RBF Capital’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

RBF Capital’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-49,122	Closed	-$287K	–	545
2022 Q4	$287K	Sell	49,122 -15,781	-24%	-$83K	0.02%	410
2022 Q3	$435K	Sell	64,903 -6,198	-9%	-$37.6K	0.04%	353
2022 Q2	$294K	Hold	71,101	–	–	0.02%	416
2022 Q1	$262K	Sell	71,101 -3,522	-5%	-$11.2K	0.02%	441
2021 Q4	$235K	Sell	74,623 -62,883	-46%	-$209K	0.01%	459
2021 Q3	$450K	Sell	137,506 -1,600	-1%	-$5.61K	0.03%	361
2021 Q2	$587K	Buy	+139,106	New	+$589K	0.03%	342

RBF Capital's CNCE Position: Q1 2023 in Review

RBF Capital sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 49,122 shares — an estimated $287K sold.

RBF Capital first reported a position in CNCE in Q2 2021 and held it in 7 quarters. The position peaked at $587K in Q2 2021. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.

RBF Capital reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
RBF Capital sold 49,122 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $287K.
RBF Capital first reported a position in Concert Pharmaceuticals, Inc. in Q2 2021 and held it in 7 quarters.
RBF Capital's Concert Pharmaceuticals, Inc. position peaked at $587K in Q2 2021.
0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.

Based on RBF Capital's 13F filing for Q1 2023, filed 16 May 2023.